LeanTaaS

LeanTaaS is a software company that uses lean principles, machine learning, and predictive analytics to digitally transform core operational processes in healthcare. This transformation increases patient access, decreases wait times, improves staff satisfaction, reduces healthcare delivery costs, and improves operational performance. LeanTaaS's cloud-based iQueue platform mathematically matches the demand for expensive, constrained healthcare resources – operating rooms, infusion chairs, imaging assets, inpatient beds, etc.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

ROCHE LAUNCHES EXOME AND CUSTOM KAPA TARGET ENRICHMENT PORTFOLIO TO EMPOWER CLINICAL RESEARCHERS

Roche | May 13, 2020

news image

KAPA HyperExome is a state-of-the-art whole exome research panel with improved performance over the on-market SeqCap portfolio, providing improved coverage and uniformity. The KAPA Target Enrichment portfolio empowers clinical researchers to process more sa...

Read More

MEDICAL

ABSCI OPENS DOOR TO NEW BIOTECHNOLOGY CAMPUS

Absci | October 23, 2021

news image

Absci Corporation the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced the opening of its new campus located in Vancouver, Washington, a few miles east of the downtown location that housed the company for the last four years. “Absci has been an incredibly positive force in the Vancouver community since establishing its headquarters here in 2016 I have fol...

Read More

QUENCH BIO EMERGES WITH $50M TO TREAT SEVERE INFLAMMATORY DISEASES

Labiotech.eu | January 27, 2020

news image

Most treatments for inflammatory diseases have single targets, such as an inflammation-promoting cytokine or a protein complex called an inflammasome. Quench Bio is taking aim at a family of proteins involved in inflammatory cell death—and it’s picked up $50 million to do so. Seeded by Atlas Venture and Arix Bioscience and incubated at Atlas since its inception in 2018, Quench's first target is gasdermin D, the best understood member of the gasdermin family of proteins. With its ...

Read More

OXITEC UNVEILS FIRST FIELD TRIAL RESULTS FOR CROP-PROTECTING GM MOTHS

Labiotech.eu | January 28, 2020

news image

A study led by Oxitec has shown for the first time that diamondback moths genetically engineered to produce only male offspring can survive in the wild, a solution that shows promise for cutting populations of the crop pest. Caterpillars of the diamondback moth Plutella xylostella are one of the most destructive pests for growers of cabbages, broccoli and cauliflowers. Rising resistance to insecticides is making it progressively more difficult for farmers to deal with the insects effectively....

Read More
news image

ROCHE LAUNCHES EXOME AND CUSTOM KAPA TARGET ENRICHMENT PORTFOLIO TO EMPOWER CLINICAL RESEARCHERS

Roche | May 13, 2020

KAPA HyperExome is a state-of-the-art whole exome research panel with improved performance over the on-market SeqCap portfolio, providing improved coverage and uniformity. The KAPA Target Enrichment portfolio empowers clinical researchers to process more sa...

Read More
news image

MEDICAL

ABSCI OPENS DOOR TO NEW BIOTECHNOLOGY CAMPUS

Absci | October 23, 2021

Absci Corporation the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced the opening of its new campus located in Vancouver, Washington, a few miles east of the downtown location that housed the company for the last four years. “Absci has been an incredibly positive force in the Vancouver community since establishing its headquarters here in 2016 I have fol...

Read More
news image

QUENCH BIO EMERGES WITH $50M TO TREAT SEVERE INFLAMMATORY DISEASES

Labiotech.eu | January 27, 2020

Most treatments for inflammatory diseases have single targets, such as an inflammation-promoting cytokine or a protein complex called an inflammasome. Quench Bio is taking aim at a family of proteins involved in inflammatory cell death—and it’s picked up $50 million to do so. Seeded by Atlas Venture and Arix Bioscience and incubated at Atlas since its inception in 2018, Quench's first target is gasdermin D, the best understood member of the gasdermin family of proteins. With its ...

Read More
news image

OXITEC UNVEILS FIRST FIELD TRIAL RESULTS FOR CROP-PROTECTING GM MOTHS

Labiotech.eu | January 28, 2020

A study led by Oxitec has shown for the first time that diamondback moths genetically engineered to produce only male offspring can survive in the wild, a solution that shows promise for cutting populations of the crop pest. Caterpillars of the diamondback moth Plutella xylostella are one of the most destructive pests for growers of cabbages, broccoli and cauliflowers. Rising resistance to insecticides is making it progressively more difficult for farmers to deal with the insects effectively....

Read More